CCR4 and asthma: A recent study circumvented this by using a human PBMC-reconstituted SCID mouse model and found that CCR4 blockade via a specific antibody ablated many of the features of inflammation, including airway eosinophilia, goblet cell hyperplasia, IgE synthesis and bronchial hyper-reactivity, thus reinforcing the idea that CCR4 is a viable target in the treatment of asthma (Perros et al., 2009).